×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: als | amyotrophic lateral sclerosis | fda | approval | medication | amylyx | relyvrio

FDA Approves Amylyx Drug to Slow ALS Progression

diagnosis pad says "amyotrophic lateral sclerosis" and some medications, thermometer around it
(Dreamstime)

Thursday, 29 September 2022 05:17 PM EDT

The U.S. Food and Drug Administration on Thursday approved Amylyx Pharmaceuticals Inc's drug for slowing progression of ALS, or amyotrophic lateral sclerosis, and potentially delaying death.

The Amylyx drug, to be sold under the brand name Relyvrio, is a combination of the generic compounds sodium phenylbutyrate and taurursodiol. The company says they work together to prevent nerve cells in the brain and spinal cord from dying prematurely.

ALS, also known as Lou Gehrig's disease, breaks down nerve cells in the brain and spinal cord that make muscles work, leading to progressive paralysis and death. It affects more than 30,000 patients in the United States, according to patient advocacy group The ALS Association.

Amylyx's case for approval was built on a recent analysis of clinical trial data that it said showed the drug slows progression of the disease and extends life expectancy by nearly 10 months.

The FDA's decision follows an approval recommendation from an outside panel of advisers in a rare reversal. The agency reconvened the panel in September to look at the new data analyzes after it had previously recommended against approving the drug in March.

Shares of the drugmaker were up nearly 7% in extended trading following the approval. 

© 2022 Thomson/Reuters. All rights reserved.


Health-News
The U.S. Food and Drug Administration on Thursday approved Amylyx Pharmaceuticals Inc's drug for slowing progression of ALS, or amyotrophic lateral sclerosis, and potentially delaying death. The Amylyx drug, to be sold under the brand name Relyvrio, is a combination of the...
als, amyotrophic lateral sclerosis, fda, approval, medication, amylyx, relyvrio
201
2022-17-29
Thursday, 29 September 2022 05:17 PM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved